Search details
1.
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Blood
; 138(20): 1966-1979, 2021 11 18.
Article
in English
| MEDLINE | ID: mdl-34132782
2.
Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling.
Blood
; 131(15): 1720-1729, 2018 04 12.
Article
in English
| MEDLINE | ID: mdl-29358175
3.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Blood
; 131(18): 2047-2059, 2018 05 03.
Article
in English
| MEDLINE | ID: mdl-29496671
4.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 187(3): 356-363, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31267520
5.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Br J Haematol
; 184(2): 242-245, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30183082
6.
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Blood
; 129(18): 2519-2525, 2017 05 04.
Article
in English
| MEDLINE | ID: mdl-28235842
7.
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Blood
; 128(6): 827-38, 2016 08 11.
Article
in English
| MEDLINE | ID: mdl-27301862
8.
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Blood
; 127(25): 3237-52, 2016 06 23.
Article
in English
| MEDLINE | ID: mdl-27143257
9.
MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.
Haematologica
; 103(9): e408-e411, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29599202
10.
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia.
Br J Haematol
; 177(5): 808-813, 2017 06.
Article
in English
| MEDLINE | ID: mdl-27073043
11.
Analyzing Spatial Transcriptomics Data Using Giotto.
Curr Protoc
; 2(4): e405, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-35384407
12.
Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma.
BME Front
; 2021: 9860123, 2021.
Article
in English
| MEDLINE | ID: mdl-37849907
13.
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
Blood Adv
; 4(1): 141-153, 2020 01 14.
Article
in English
| MEDLINE | ID: mdl-31935288
14.
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
J Clin Oncol
; 38(11): 1198-1208, 2020 04 10.
Article
in English
| MEDLINE | ID: mdl-32083995
15.
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Blood Cancer J
; 10(1): 12, 2020 01 31.
Article
in English
| MEDLINE | ID: mdl-32005797
16.
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
J Clin Oncol
; 36(27): 2755-2761, 2018 09 20.
Article
in English
| MEDLINE | ID: mdl-30044692
17.
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia.
Blood Adv
; 4(18): 4550-4553, 2020 09 22.
Article
in English
| MEDLINE | ID: mdl-32956451
18.
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Blood Adv
; 3(19): 2800-2803, 2019 10 08.
Article
in English
| MEDLINE | ID: mdl-31570491
Results
1 -
18
de 18
1
Next >
>>